In the following video, Motley Fool health-care analyst David Williamson discusses a new E.U. approval for Gilead (GILD +0.42%) for its quad pill HIV drug cocktail, which has shares up 2% to near all-time highs. David tells investors why this is just one more piece to the puzzle for Gilead, as it continues to build its empire in the treatment of HIV.
